181,031 Shares in AbCellera Biologics Inc. $ABCL Bought by Virtu Financial LLC

Virtu Financial LLC bought a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 181,031 shares of the company’s stock, valued at approximately $619,000. Virtu Financial LLC owned about 0.06% of AbCellera Biologics at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ABCL. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of AbCellera Biologics during the 4th quarter worth about $26,938,000. Goldman Sachs Group Inc. lifted its holdings in AbCellera Biologics by 1,636.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,344,485 shares of the company’s stock worth $14,858,000 after purchasing an additional 4,094,268 shares during the last quarter. Bank of America Corp DE lifted its holdings in AbCellera Biologics by 977.8% in the 3rd quarter. Bank of America Corp DE now owns 2,418,304 shares of the company’s stock worth $12,164,000 after purchasing an additional 2,193,939 shares during the last quarter. Tudor Investment Corp ET AL boosted its position in AbCellera Biologics by 146.0% during the fourth quarter. Tudor Investment Corp ET AL now owns 1,796,010 shares of the company’s stock worth $6,142,000 after purchasing an additional 1,065,888 shares during the period. Finally, Two Sigma Investments LP boosted its position in AbCellera Biologics by 25.9% during the third quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company’s stock worth $26,031,000 after purchasing an additional 1,064,290 shares during the period. 61.42% of the stock is currently owned by institutional investors.

AbCellera Biologics Stock Up 3.8%

Shares of NASDAQ ABCL opened at $5.74 on Tuesday. AbCellera Biologics Inc. has a 12 month low of $2.74 and a 12 month high of $6.79. The company has a market cap of $1.75 billion, a P/E ratio of -11.96 and a beta of 1.17. The business’s 50 day moving average is $4.85 and its two-hundred day moving average is $4.03.

AbCellera Biologics (NASDAQ:ABCL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.08. The company had revenue of $8.31 million during the quarter, compared to analysts’ expectations of $5.41 million. AbCellera Biologics had a negative return on equity of 14.86% and a negative net margin of 181.75%.During the same period in the prior year, the business earned ($0.15) earnings per share. Sell-side analysts expect that AbCellera Biologics Inc. will post -0.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABCL. Cantor Fitzgerald initiated coverage on shares of AbCellera Biologics in a research report on Tuesday, May 5th. They issued an “overweight” rating and a $7.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AbCellera Biologics in a report on Monday, April 20th. Wall Street Zen lowered shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, JonesTrading initiated coverage on shares of AbCellera Biologics in a report on Friday, April 10th. They issued a “buy” rating and a $11.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.80.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.